Zelira Therapeutics Ltd
ZLD
Company Profile
Business description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
Contact
101 St George’s Terrace
Level 3
PerthWA6000
AUST: +61 865580886
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
8
Stocks News & Analysis
stocks
ASX gold miner under pressure to sell by activist investor
Activist investor presses gold miner on selling to larger players.
stocks
Ask the Analyst: Will Amcor lose its dividend aristocrat status?
When consistency becomes constraint.
stocks
Chart of the Week: We see opportunity in this beaten down industrial player
The market sees risks and are discounting the shares excessively.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,866.40 | 69.10 | -0.77% |
| CAC 40 | 8,244.29 | 0.00 | 0.00% |
| DAX 40 | 24,944.95 | 149.01 | 0.60% |
| Dow JONES (US) | 51,561.93 | 874.86 | 1.73% |
| FTSE 100 | 10,360.32 | 28.02 | 0.27% |
| HKSE | 25,127.69 | 125.71 | -0.50% |
| NASDAQ | 26,830.96 | 23.02 | -0.09% |
| Nikkei 225 | 66,331.86 | 1,138.83 | -1.69% |
| NZX 50 Index | 13,124.54 | 22.93 | 0.18% |
| S&P 500 | 7,584.31 | 30.63 | 0.41% |
| S&P/ASX 200 | 8,635.10 | 70.00 | -0.80% |
| SSE Composite Index | 4,050.56 | 7.22 | -0.18% |